About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 50 record(s)
Req # A-2022-09230
All correspondence between PMPRB Executive Director Doug Clark and the Minister of Health Jean-Yves Duclos (including the Minister’s staff), or Deputy Minister of Health Stephen Lucas (including the Deputy Minister’s staff), about the PMPRB October 2022 revised draft Guidelines and the resignation of PMPRB Acting Chairperson, Melanie Bourassa-Forcier. “Correspondence” includes written correspondence, call notes, email, text messaging, instant messaging, and any other form of electronic communication.Organization: Patented Medicine Prices Review Board Canada
February 2023
Req # A-2022-09231
Copies of all PMPRB Board minutes and materials (briefing materials, presentations, staff recommendations) pertaining to the October 2022 revised draft Guidelines.Organization: Patented Medicine Prices Review Board Canada
February 2023
Req # A-2022-09622
All correspondence and emails from the federal Health Minister Jean-Yves Duclos to the Patented Medicines Prices Review Board in the period between October 1, 2022 and December 5, 2022 regarding new draft guidelines and the consultation process and all responses to the federal Minister of Health and Health Canada from the (then) acting chairperson of the Patented Medicines Prices Review Board Mélanie Bourassa-Forcier.Organization: Patented Medicine Prices Review Board Canada
February 2023
Nothing to report this month
Organization: Patented Medicine Prices Review Board Canada
Req # A-2019-00003
•All records concerning or related to the federal government’s Directive on Automated Decision-Making that was prepared by or provided to the PMPRB. (January 1, 2019 to May 2, 2019). •A list of all pending access to information requests at the PMPRB (as of May 2, 2019). •All records relating to the impact of the pending amendments on national pharmacare or the impact of national pharmacare on the pending amendments (From May 2, 2019 to March 1, 2022). •The agenda and minutes for any meetings held by PMPRB executives between January 1, 2018 and May 1, 2019 that concerned the pending amendments. •All revisions or redrafts of the Regulatory Impact Analysis Statement (date of my first request to May 2, 2019). •All records relating to the new basket of countries under the pending amendments, including the inclusion or exclusion of particular countries (date of my first request down to May 2, 2019). •All records relating to the adoption of new pricing factors under the pending amendments (date of my first request down to May 2, 2019). •All records relating to changes in the reporting requirements for patentees under the pending amendments, especially the requirement to report confidential discounts or rebates (date of my first request down to May 2, 2019). •All records relating to a possible decision to distinguish between existing and new medicines in the application of the pending regulations (whether concerning pricing rules, reporting requirements, or any other legal obligation) (date of my first request down to May 2, 2019). •All studies, reports, or other documents prepared by or held by the PMPRB which deal with changes to the content of the pending regulations or the guidelines which are being developed (date of my first request down to May 2, 2019). •All communications regarding the proposed amendments between the PMPRB and one or more of the following organizations: Health Canada, ISED, or CIPO (date of my first request down to May 2, 2019). •All letters or other communications received between September 1, 2018 and May 1, 2019 that question or criticize the pending amendments (date of my first request down to May 2, 2019). •All records generated by the PMPRB or another federal government entity that comment on or analyze the report prepared by Mr. David Dodge (August 23, 2018 to May 2, 2019). •A copy of all training presentations concerning the pending amendments that were held or were supposed to be held between Setptember 1, 2019 and May 1, 2019.Organization: Patented Medicine Prices Review Board Canada
March 2022
Req # A-2022-05127
Copies of all emails to/from Douglas Clark, Melanie Bourassa-Forcier, Tanya Potashnik and Health Canada officials from November 1, 2021 to January 31, 2022.Organization: Patented Medicine Prices Review Board Canada
March 2022
Req # A-2020-18439
Copies of all email exchanges between the PMPRB and pCPA and CADTH members in the provincial offices from June 1, 2019 to November 19, 2020.Organization: Patented Medicine Prices Review Board Canada
February 2022
Req # A-2021-10646
Provide the preparation documents (excluding PowerPoint), meeting summaries and emails related to meetings and communications between PMPRB executives and Boehringer Ingelheim over planned reforms to the PMPRB Guidelines from June 1, 2019 to June 8, 2021. Do not include emails related to Zoom, Microsoft Teams or other such mediums for the purposes of conducting the meeting, only the content of the meeting itself.Organization: Patented Medicine Prices Review Board Canada
February 2022
Req # A-2021-10666
Provide the preparation documents (excluding PowerPoint), meeting summaries and emails related to meetings and communications between PMPRB executives and Sanofi Canada over planned reforms to the PMPRB Guidelines from June 1, 2019 to June 8, 2021. Do not include emails related to Zoom, Microsoft Teams or other such mediums for the purposes of conducting the meeting, only the content of the meeting itself.Organization: Patented Medicine Prices Review Board Canada
February 2022
Req # A-2021-07238
Copies of all information, data, document, or correspondence concerning the PMPRB's classification of the following drug products: NOVORAPID and FIASP, each a product of NOVO NORDISK CANADA INC, a corporation located at 101-2476 Argentia Road, Mississauga, Ontario, Canada L5N 6M1, including but not limited to classifications based on drug product line extensions, similar chemical entities, comparable dosages, or a reasonable relationship between the two drugs, as well as any other analysis, comments, or information related to the classification of these two drugs.Organization: Patented Medicine Prices Review Board Canada
May 2021